2023
Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias
DiDomizio E, Chandra D, Nichols L, Villanueva M, Altice F. Challenges to Achieving HCV Micro-Elimination in People With HIV in the United States: Provider Perspectives and the Role of Implicit Bias. Health Promotion Practice 2023, 24: 998-1008. PMID: 37440258, DOI: 10.1177/15248399231169928.Peer-Reviewed Original ResearchConceptsNominal group techniqueHealth care decisionsProvider perspectivesEligibility criteriaHIV/HCVEffective antiviral medicationsPatient eligibility criteriaFacilitators of treatmentMicro-EliminationHCV treatmentAntiviral medicationsOpioid epidemicProvider knowledgePatient involvementPatient engagementDifferent clinicsRelated stigmaHCVCare decisionsHIVPatientsTreatmentGroup sessionsMost barriersFocus group sessionsFuture Directions for HIV/HCV Care: Lessons Learned From Local Evaluation Projects in Texas and Connecticut and Implications for Practice and Health Promotion
Villanueva M. Future Directions for HIV/HCV Care: Lessons Learned From Local Evaluation Projects in Texas and Connecticut and Implications for Practice and Health Promotion. Health Promotion Practice 2023, 24: 1050-1054. PMID: 37439561, DOI: 10.1177/15248399231169919.Peer-Reviewed Original ResearchConceptsServices Administration's Special ProjectsHCV elimination goalsSystem-level barriersHCV careHCV cureHepatitis CElimination goalsHealth promotionYale University SchoolIndividualized approachPriority populationsLocal implementation strategiesLevel barriersUniversity SchoolImplementation strategiesHCVHIVPatientsSan AntonioEvaluation projectCare
2022
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS And Behavior 2022, 27: 119-133. PMID: 35776253, PMCID: PMC9663279, DOI: 10.1007/s10461-022-03749-8.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsHIV/HCVDAA treatmentHCV treatmentHIV/HCV Co-infectionDAA treatment uptakeHCV Co-InfectionPatient-level barriersHCV diseaseAdherence supportHepatitis CActing antiviralsTreatment uptakeCo-InfectionTreatment barriersHCVTreatmentPWHAntiviralsQualitative interviewsHIVDiseaseDiagnosisPersonsUptake
2020
A Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population
Adamson PC, Miceli J, Shiferaw B, Villanueva MS, Canterino JE. A Colocalized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population. The American Journal Of Medicine 2020, 133: 705-712. PMID: 31987799, DOI: 10.1016/j.amjmed.2019.12.028.Peer-Reviewed Original ResearchConceptsChronic HCVPrimary care practicesClinic practiceHCV clinicChronic hepatitis C virus (HCV) infectionCare practicesHepatitis C virus infectionCascade of careHCV antibody testHCV testing dataC virus infectionChronic HCV infectionPrevalence of HCVPrimary care patientsHigh-prevalence populationsHCV cascadeHCV infectionCare patientsMultivariable analysisRetrospective studyClinic populationPrevalence populationsVirus infectionHigher oddsHCV